Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
07:45pm, Monday, 17'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to cont
Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors
06:56pm, Monday, 17'th Jun 2024
Moderna (MRNA) concluded the recent trading session at $137.90, signifying a -1.52% move from its prior day's close.
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). In
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
07:41am, Monday, 17'th Jun 2024
Biotechnology firm Moderna Inc. NASDAQ: MNRA made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA (mRNA) technology for the development of innov
NEW YORK, NY / ACCESSWIRE / June 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). In
Moderna Just Gave Investors Another Reason to Buy the Stock
09:45am, Sunday, 16'th Jun 2024
Moderna's combination vaccine delivered positive news from the clinic. It is yet another win for Moderna's innovative mRNA-based approach.
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
02:55am, Saturday, 15'th Jun 2024
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent CO
NEW YORK, NY / ACCESSWIRE / June 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). In
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
03:37pm, Thursday, 13'th Jun 2024
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA). Such investors are advise
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
11:00am, Thursday, 13'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). In
Moderna says new-generation COVID vaccine more effective than Spikevax
07:28am, Thursday, 13'th Jun 2024
Moderna Inc. MRNA, -0.45% said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy in adults compared to its original vaccine dubbed Spikevax.
Moderna's next-gen COVID vaccine shows non-inferiority to current shot
07:16am, Thursday, 13'th Jun 2024
Moderna said on Thursday its next-generation COVID-19 vaccine candidate met its main goal in a late-stage study by showing vaccine efficacy that was non-inferior compared with the company's commercial
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company's Next Generation COVID-19 Vaccine
07:00am, Thursday, 13'th Jun 2024
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older Hi
7 Struggling Stocks to Sell Before July 2024
12:30pm, Wednesday, 12'th Jun 2024
The stock market's surge continues, with several major market indices making new all-time highs recently. The explosion of artificial intelligence and semiconductor activity has been a windfall for te
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
11:00am, Wednesday, 12'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). In
